Company expects cash runway to fund operations and studies through 2027
DiaMedica anticipates R&D expenses to increase moderately as clinical programs expand
G&A expenses expected to remain steady compared to recent periods
Overview
US biopharma firm's Q2 net loss and loss per share beat analyst expectations
Company ended Q2 with $43.5 mln in cash and investments, runway expected through 2027
Higher R&D expenses reflect expansion of clinical trials for preeclampsia and stroke
Result Drivers
R&D EXPANSION - Higher research and development expenses driven by expanded clinical trials for preeclampsia, fetal growth restriction, and stroke
PIPELINE PROGRESS - Positive topline results in Phase 2 preeclampsia trial and completion of first fetal growth restriction cohort highlighted as key milestones
G&A COSTS - Slight increase in general and administrative expenses due to higher share-based compensation and professional fees
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for DiaMedica Therapeutics Inc is $13.00, about 92.6% above its August 7 closing price of $6.75
DMAC•
